Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Cash (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Change in Cash data on record, last reported at $15.7 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 3461.37% year-over-year to $15.7 million; the TTM value through Dec 2025 reached $75.2 million, up 218.67%, while the annual FY2025 figure was $75.2 million, 218.67% up from the prior year.
  • Change in Cash reached $15.7 million in Q4 2025 per MIRM's latest filing, down from $53.9 million in the prior quarter.
  • Across five years, Change in Cash topped out at $147.8 million in Q2 2023 and bottomed at -$69.3 million in Q2 2024.
  • Average Change in Cash over 5 years is $7.8 million, with a median of $3.5 million recorded in 2021.
  • Peak YoY movement for Change in Cash: tumbled 273.23% in 2024, then skyrocketed 3461.37% in 2025.
  • A 5-year view of Change in Cash shows it stood at $75.5 million in 2021, then plummeted by 110.27% to -$7.8 million in 2022, then tumbled by 115.74% to -$16.7 million in 2023, then surged by 97.22% to -$466000.0 in 2024, then surged by 3461.37% to $15.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $15.7 million in Q4 2025, $53.9 million in Q3 2025, and $16.4 million in Q2 2025.